Show simple item record

dc.contributor.authorBello, Shaibu Oricha
dc.contributor.authorYunusa, Abdulmajeed
dc.contributor.authorIgumbor, Ehimario Uche
dc.date.accessioned2023-04-20T13:16:35Z
dc.date.available2023-04-20T13:16:35Z
dc.date.issued2023
dc.identifier.citationBello, S. O. et al. (2023). Innovative, rapid, high-throughput method for drug repurposing in a pandemic—A case study of SARS-CoV-2 and Covid-19. Frontiers in Pharmacology, 14, 1130828. https://doi.org/10.3389/fphar.2023.1130828en_US
dc.identifier.issn1663-9812
dc.identifier.urihttps://doi.org/10.3389/fphar.2023.1130828
dc.identifier.urihttp://hdl.handle.net/10566/8849
dc.description.abstractSeveral efforts to repurpose drugs for COVID-19 treatment have largely either failed to identify a suitable agent or agents identified did not translate to clinical use. Reasons that have been suggested to explain the failures include use of inappropriate doses, that are not clinically achievable, in the screening experiments, and the use of inappropriate pre-clinical laboratory surrogates to predict efficacy. In this study, we used an innovative algorithm, that incorporates dissemination and implementation considerations, to identify potential drugs for COVID-19 using iterative computational and wet laboratory methods. The drugs were screened at doses that are known to be achievable in humans. Furthermore, inhibition of viral induced cytopathic effect (CPE) was used as the laboratory surrogate to predict efficacy.en_US
dc.language.isoenen_US
dc.publisherFrontiers Mediaen_US
dc.subjectCovid-19en_US
dc.subjectPublic healthen_US
dc.subjectDrugsen_US
dc.subjectPharmacologyen_US
dc.titleInnovative, rapid, high-throughput method for drug repurposing in a pandemic—A case study of SARS-CoV-2 and Covid-19en_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record